Anterogen.Co.,Ltd.
Financials
Valuation Metrics
Anterogen.Co.,Ltd.'s Market Cap is ₩1722B. At end of 2025 it was ₩4688B. Ranked #915 of 2,436 in KR market (top 38%), #433 of 1,649 on KOSDAQ (top 26%), #102 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.20B KRW | KR#915/2,436 Sec#102/234 |
| Revenue | 8.06B KRW | KR#2,306/2,436 Sec#183/234 |
| Net Income | -1.56B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 84.79B KRW | KR#1,866/2,436 Sec#154/234 |
| Net Assets | 83.83B KRW | KR#1,521/2,436 Sec#126/234 |
| Employees | 29 | KR#2,184/2,436 Sec#202/234 |
| Value | ||
| P/B | 2.05x | KR#1,961/2,436 Sec#145/234 |
| P/S | 21.37x | KR#2,337/2,436 Sec#184/234 |
| FCF Yield | -0.65% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -1.86% | KR#1,607/2,436 Sec#112/234 |
| ROA | -1.84% | KR#1,685/2,436 Sec#120/234 |
| Op. Margin | -30.25% | KR#2,180/2,436 Sec#153/234 |
| Revenue Growth | 32.49% | KR#446/2,436 Sec#39/234 |
| Financial Health | ||
| Debt Ratio | 101.14% | KR#328/2,436 Sec#42/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -1.12B KRW | KR#1,287/2,436 Sec#97/234 |
| Cash | 1.68B KRW | KR#2,276/2,436 Sec#218/234 |
| Current Ratio | 63.40x | KR#4/2,436 Sec#3/234 |
| Performance | ||
| 1Y Return | -23.68% | KR#1,419/2,436 Sec#119/234 |
| 1M Return | -18.82% | KR#2,148/2,436 Sec#205/234 |
| From 52W High | -72.15% | KR#2,191/2,436 Sec#197/234 |
| 1Y MDD | -74.26% | KR#2,116/2,436 Sec#190/234 |
| Trading | ||
| Volume | 47,476 shares | KR#1,051/2,436 Sec#100/234 |
| Foreign Own. | 3.51% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -156 KRW | KR—/2,436 Sec—/234 |
| BPS | 8,378 KRW | KR#1,050/2,436 Sec#71/234 |
Company Info
Antrogen, established in 2000 and listed on KOSDAQ in 2016, is a specialized stem cell therapy bio-venture. In 2012, it gained the world's first marketing approval for Cupistem, an adipose-derived stem cell product for Crohn's fistula, and holds exclusive domestic sales rights for pulmonary hypertension treatments Remodulin and Tyvaso. Through its diverse disease pipeline, Antrogen is expanding its business and strengthening its competitive edge in rare and intractable disease treatments. It is headquartered in Geumcheon-gu, Seoul.